Industry News
Biotechnology Industry News

Chinook launches a new biotech with major VCs in China to double down on kidney disease R&D
Chinook launches a new biotech with major VCs in China to double down on kidney disease R&D badams Tue, 11/30/2021 - 03:45
RAGE against diabetes complications: Novel drug tamps down tissue damage in mice
RAGE against diabetes complications: Novel drug tamps down tissue damage in mice arlene.weintraub Mon, 11/29/2021 - 12:45
Could common antihistamines be the key to boosting immuno-oncology treatments?
Could common antihistamines be the key to boosting immuno-oncology treatments? arlene.weintraub Mon, 11/29/2021 - 09:23
Turnstone teams up with Moffitt to race TIL cell therapies into the clinic
Turnstone teams up with Moffitt to race TIL cell therapies into the clinic ntaylor Mon, 11/29/2021 - 08:08
Is molnupiravir a turkey? Merck slips out drop in efficacy of COVID-19 antiviral over Thanksgiving period
Is molnupiravir a turkey? Merck slips out drop in efficacy of COVID-19 antiviral over Thanksgiving period ntaylor Mon, 11/29/2021 - 06:19
Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M round
Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M round badams Mon, 11/29/2021 - 04:49
FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death
FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient death klahucik Wed, 11/24/2021 - 08:47
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet
Chasing Regeneron, Pfizer posts data on $250M cardiovascular bet ntaylor Wed, 11/24/2021 - 08:23
Kymera’s first-in-class protein degrader shows potential to boost cancer immunotherapy
Kymera's first-in-class protein degrader shows potential to boost cancer immunotherapy aliu Wed, 11/24/2021 - 07:10
Acorda CMO hits the exit, landing Pharnext job with oversight of phase 3 neurological disorder trial
Acorda CMO hits the exit, landing Pharnext job with oversight of phase 3 neurological disorder trial ntaylor Wed, 11/24/2021 - 05:52
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO
Rafael resets after phase 3 flop, parting ways with 5 execs and reinstating telecom tycoon as CEO ntaylor Tue, 11/23/2021 - 08:03
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off?
AstraZeneca, after years of delays and spiraling costs, opens Cambridge R&D site. Will the bet pay off? ntaylor Tue, 11/23/2021 - 05:06
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus
Vaccibody, now Nykode, celebrates new name with a Regeneron deal worth $900M-plus badams Tue, 11/23/2021 - 03:28
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead badams Mon, 11/22/2021 - 10:49
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets badams Mon, 11/22/2021 - 08:57
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal
Xencor finally finds buyer for onetime lead drug, offloading autoimmune asset to Tesaro co-founder in backloaded deal ntaylor Mon, 11/22/2021 - 08:33
Sanifit, having put Spain’s biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data
Sanifit, having put Spain's biotech scene on the map, lands $231M Vifor buyout ahead of phase 3 data ntaylor Mon, 11/22/2021 - 06:11
Twist nabs antibody discovery biotech Abveris for $190M a week after spinning out COVID unit
Twist nabs antibody discovery biotech Abveris for $190M a week after spinning out COVID unit badams Mon, 11/22/2021 - 05:59
Connect Biopharma touts positive results for Dupixent rival, but shares halved as investors await hard data
Connect Biopharma touts positive results for Dupixent rival, but shares halved as investors await hard data badams Mon, 11/22/2021 - 04:40
‘What it takes’: As Lilly’s Alzheimer’s drug approaches FDA, launch leader feels ‘amplified’ sense of excitement
'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement aarmstrong Fri, 11/19/2021 - 12:44

